San Diego, CA and Boulder, CO — Inocras, a leading innovator in whole genome sequencing and bioinformatics, and Watchmaker Genomics, an expert in genomic tool development for demanding sequencing applications, are thrilled to announce an expansion of their partnership to deliver solutions aimed at accelerating insights for patients and researchers.
Earlier this year, Inocras launched its CancerVision assay, employing target enhanced whole genome sequencing (TE-WGS) for comprehensive analysis of solid tumors。This novel methodology enriches WGS insights with targeted deep sequencing of clinically relevant regions, delivering the breadth of whole genome analysis and the depth required for precise characterization of key oncogenic drivers and actionable mutations. By effectively differentiating between tumor-specific alterations and inherited sequences, the assay significantly increases the accuracy of somatic variant detection across diverse populations – with sensitivity above 99% for both single nucleotide variants (SNVs) and insertions/deletions (indels).
During development, Inocras rigorously tested several library preparation chemistries and ultimately selected the Watchmaker 酶法片段化 DNA 文库制备试剂盒 for its high library conversion efficiency, low-bias sequence coverage, and excellent sequence accuracy with challenging formalin-fixed, paraffin-embedded (FFPE) tissues.
“We’re proud to demonstrate the power of whole genome sequencing and analytics through our diagnostics products. Our collaboration with Watchmaker has been important in driving this innovation, and we are excited to continue our partnership on upcoming laboratory-developed assays,” said Stephanie Ferguson, Inocras’s Chief Clinical Operations Officer. “Our shared commitment to excellence has been a catalyst for innovation.”
“We are impressed with Inocras’s sophisticated approach for improving somatic mutation detection accuracy, and we look forward to collaborating on future assays that harness the power of whole genome insights,” said Kerri Stellato, Chief Commercial Officer at Watchmaker.
About Inocras Inc:
Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics for cancer and rare diseases. The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone. For more information about Inocras and the company’s services, please visit www.inocras.com 或 扫描下方二维码。
关于Watchmaker Genomics
Watchmaker Genomics（沃奇酶科）运用先进的酶学技术，实现各种DNA和RNA读取、写入和编辑方面的突破性应用。该公司将蛋白质工程领域的专长与大规模酶制造技术相结合，以满足高速增长的临床基因组学应用市场对产品质量、性能和生产规模方面的严苛要求。Watchmaker 的产品线包括新一代测序、合成生物学及分子诊断应用所需的精准酶及成套试剂盒。For more information, please visit www.watchmakergenomics.com or find us on 扫描下方二维码。
Media Contacts
Jen Pavlica
Sr. Product Manager, Strategic
Watchmaker Genomics
jen.pavlica@watchmakergenomics.com
Jordan Younis
Sr. Marketing Manager
Inocras, Inc.
jyounis@inocras.com
